Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...

A new study published in the Journal of American Medical Association showed that dupilumab (Dupixent), used for treating ...

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...

The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Biological drugs have improved the lives of many people with severe asthma. However, a new study from Karolinska Institutet ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid (BP), a condition that predominantly affects ...

Among patients with COPD and type 2 inflammation, investigator-reported emphysema did not change benefits seen with dupilumab ...

Bio-Thera Solutions, Ltd., a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and ...

Key findings of subgroup analyses included an observed increased psoriasis risk in patients without atopic comorbidities (HR 1.42, 95% CI 1.06-1.89) and those with pretreatment immunoglobulin E (IgE) ...